Head to Head Survey: Pro-Dex (NASDAQ:PDEX) & IceCure Medical (NASDAQ:ICCM)

IceCure Medical (NASDAQ:ICCM) and Pro-Dex (NASDAQ:PDEX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, profitability, analyst recommendations, institutional ownership and valuation.

Risk and Volatility

IceCure Medical has a beta of 0.45, suggesting that its stock price is 55% less volatile than the S&P 500. Comparatively, Pro-Dex has a beta of 0.06, suggesting that its stock price is 94% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for IceCure Medical and Pro-Dex, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IceCure Medical	2	0	3	0	2.20
Pro-Dex	0	1	2	0	2.67

IceCure Medical presently has a consensus target price of $52.50, indicating a potential upside of 2,460.98%. Pro-Dex has a consensus target price of $74.00, indicating a potential upside of 10.60%. Given IceCure Medical’s higher probable upside, equities research analysts plainly believe IceCure Medical is more favorable than Pro-Dex.

Earnings & Valuation

This table compares IceCure Medical and Pro-Dex”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IceCure Medical	$3.38 million	2.08	-$15.06 million	($8.52)	-0.24
Pro-Dex	$77.55 million	2.76	$13.66 million	$4.13	16.20

Pro-Dex has higher revenue and earnings than IceCure Medical. IceCure Medical is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

0.6% of IceCure Medical shares are held by institutional investors. Comparatively, 15.3% of Pro-Dex shares are held by institutional investors. 2.4% of IceCure Medical shares are held by insiders. Comparatively, 45.9% of Pro-Dex shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares IceCure Medical and Pro-Dex’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
IceCure Medical	-427.67%	-174.26%	-112.58%
Pro-Dex	17.62%	25.13%	16.02%

Summary

Pro-Dex beats IceCure Medical on 11 of the 14 factors compared between the two stocks.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.

About Pro-Dex

Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company's products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.